Although itolizumab did not improve response rates at Day 29 for patients with acute GVHD, the therapy showed significant ...

Equillium's itolizumab showed improved longer-term outcomes in aGVHD despite missing primary endpoints. FDA feedback on ...

Despite missing its primary endpoint, Equillium is pushing ahead with itolizumab citing its complete response by day 99.

The most elusive planetary aurora in the Solar System has finally been revealed in all its gently glowing glory.

Arctic sea ice had its weakest winter buildup since record-keeping began 47 years ago, a symptom of climate change that will ...